Skip to main content
Premium Trial:

Request an Annual Quote

Genotype Product Deals Drive 174-Percent Growth in Illumina's Q3 Revenues

NEW YORK (GenomeWeb News) - Illumina yesterday reported a 174-percent increase in total revenue for the third quarter of 2006, as compared with the same period last year.
 
Citing heightened demand for its BeadChip product line, the company reported total revenue of $53.5 million for the quarter ending Oct. 1, compared with $19.5 million in the third quarter of 2005. 
 
Revenues from product sales nearly tripled to $46.9 million from $16.3 million in the prior-year period.
 
The company cited recent genotyping deals with GlaxoSmithKline, Duke University, Massachusetts General Hospital, and Harvard Medical School as examples of demand for its products.
 
Illumina reported net income of $16.2 million for the quarter, including total non-cash stock compensation expense of $3.8 million, compared to a net loss of $1.5 million in the third quarter of 2005.
 
R&D spending rose to $7.7 million from $7 million in the prior-year period.
 
Illumina ended the third quarter with cash and short-term investments worth $169.9 million, of which $44.2 million was in cash and cash equivalents.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.